Last $183.24 USD
Change Today -4.81 / -2.56%
Volume 2.1M
ALXN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (ALXN) Snapshot

Open
$186.81
Previous Close
$188.05
Day High
$189.72
Day Low
$181.67
52 Week High
12/3/14 - $203.30
52 Week Low
04/15/14 - $136.37
Market Cap
36.3B
Average Volume 10 Days
1.5M
EPS TTM
$3.37
Shares Outstanding
198.3M
EX-Date
--
P/E TM
54.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for ALEXION PHARMACEUTICALS INC (ALXN)

alexion pharmaceuticals inc (ALXN) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (ALXN) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

alexion pharmaceuticals inc (ALXN) Top Compensated Officers

Co-Founder, Chairman of the Board and Chief E...
Total Annual Compensation: $1.2M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $615.0K
Global Head of Research & Development and Exe...
Total Annual Compensation: $547.0K
Chief Strategy & Portfolio Officer and Senior...
Total Annual Compensation: $325.0K
Chief Operating Officer and Director
Total Annual Compensation: $610.0K
Compensation as of Fiscal Year 2013.

alexion pharmaceuticals inc (ALXN) Key Developments

Alexion Pharmaceuticals, Inc. Announces Executive Changes, Effective April 1, 2015

Alexion Pharmaceuticals, Inc. announced that its Board of Directors has appointed David L. Hallal as the Company's Chief Executive Officer (CEO), effective April 1, 2015. Mr. Hallal currently serves as Alexion's Chief Operating Officer (COO) and is a Director of the Board. He will succeed Leonard Bell, M.D., Chairman and CEO, who will retire as CEO and continue to serve as Chairman of the Board. Dr. Bell was the principal founder of Alexion in 1992 and has served as CEO for the past 23 years. Mr. Hallal, 48, has more than 25 years of experience in the biopharmaceutical industry. Since joining Alexion in 2006 to initiate commercial operations, he has served in key leadership positions of increasing responsibility, including as the Company's first Chief Commercial Officer, and was appointed COO and to the Board of Directors in 2014. Mr. Hallal has played a principal role in leading many of the Company's key growth initiatives, including the highly successful launches of Soliris (eculizumab) in PNH and aHUS and the building of Alexionâ s 50-country operating platform.

Alexion Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year 2015 and Tax Rate Guidance for the Years 2016 and 2017; Reports Impairment Charges for the Fourth Quarter Ended December 31, 2014

Alexion Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net product sales of $599,476,000 compared to $441,909,000 for the same period in 2013. Operating income was $203,695,000 against $138,072,000 a year ago. Income before income taxes was $205,341,000 against $137,977,000 a year ago. Net income was $153,332,000 or $0.76 per diluted share compared to net loss of $18,992,000 or $0.10 per diluted share, in fourth quarter of 2013. Non-GAAP net income was $265,983,000 or $1.30 per diluted share in compared to non-GAAP net income of $177,749,000 or $0.87 per diluted share in the fourth quarter of 2013. For the full year, the company reported net product sales of $2,233,733,000 compared to $1,551,346,000 for the same period in 2013. Operating income was $868,706,000 against $528,010,000 a year ago. Income before income taxes was $872,107,000 against $526,269,000 a year ago. Net income was $656,912,000 or $3.26 per diluted share compared to $252,895,000 or $1.27 per diluted share, in fourth quarter of 2013. Non-GAAP net income was $1,065,921,000 or $5.21 per diluted share in compared to non-GAAP net income of $624,206,000 or $3.08 per diluted share in the fourth quarter of 2013. For the fourth quarter, the company reported impairment of intangible assets was $8,050,000 against $33,521,000 a year ago. For the full year 2015, worldwide net product sales are expected to be within a range of $2.55 to $2.6 billion, which includes an approximately negative 5%, or $135 million, foreign exchange impact compared to 2014 exchange rates. Non-GAAP earnings per share for the year are expected to be $5.60 to $5.80, which includes an approximately $0.30 negative foreign exchange impact compared to 2014 exchange rates. On a constant currency basis, the company’s non-GAAP EPS guidance would have been approximately $0.30 higher. The non-GAAP effective tax rate is expected to be approximately 7% to 9%. 2015 pretax operating results are expected to deliver similar margins compared to 2014. The company now anticipated that its tax rate will be 12% to 13% in 2016 The company now anticipated that its tax rate will be 14% to 16% in 2017.

Alexion Pharmaceuticals, Inc. to Report Q4, 2014 Results on Jan 29, 2015

Alexion Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 9:00 AM, Eastern Standard Time on Jan 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $183.24 USD -4.81

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Croda International PLC 2,657 GBp -49.00
Dr Reddy's Laboratories Ltd 3,233 INR -130.05
Regeneron Pharmaceuticals Inc $416.66 USD +2.02
Sigma-Aldrich Corp $137.52 USD -0.13
Symrise AG €58.10 EUR -0.61
View Industry Companies
 

Industry Analysis

ALXN

Industry Average

Valuation ALXN Industry Range
Price/Earnings 78.3x
Price/Sales 17.9x
Price/Book 11.9x
Price/Cash Flow 76.9x
TEV/Sales 17.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit www.alexionpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.